Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Aug 25, 2020 8:09am EDT

Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH

Aug 20, 2020 7:00am EDT

Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET

Jul 27, 2020 7:00am EDT

Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study

Jul 20, 2020 7:00am EDT

Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds

Jul 15, 2020 7:00am EDT

Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly

Jul 06, 2020 8:00am EDT

Can-Fite Announces $3.4 Million Registered Direct Offering

Jun 30, 2020 7:00am EDT

Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period

Jun 10, 2020 8:00am EDT

Can-Fite Announces $8.0 Million Registered Direct Offering

Jun 09, 2020 7:00am EDT

Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S.

Jun 08, 2020 7:25am EDT

Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020

  • arrow_back
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 37
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2023 Can-Fite All Rights Reserved

BrandWiz - Branding